FibroGen to Participate at William Blair Biotech Focus Conference 2022

Rhea-AI Summary

SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen (NASDAQ: FGEN) announces CEO Enrique Conterno will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 during the week of July 11, 2022. A webcast will be available on July 11 at 9:00am ET on the FibroGen Investors webpage, with a replay accessible for 30 days. FibroGen is dedicated to developing first-in-class therapeutics, notably Pamrevlumab for various cancers and disorders, and Roxadustat, an approved treatment for anemia in multiple countries.

SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022.

A webcast of the event will be available Monday, July 11 at 9:00am ET on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. The replay will be available for approximately 30 days.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and Duchenne muscular dystrophy (DMD). Roxadustat (爱瑞卓^®, EVRENZO^TM) is currently approved in China, Japan, Europe, Chile, South Korea, and Russia for the treatment of anemia in CKD patients on dialysis and patients not on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS), and in Phase 3 clinical development in China for treatment of chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.

Contact:
FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com

Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

FAQ

When will FibroGen's CEO speak at the William Blair Biotech Focus Conference?

Enrique Conterno, CEO of FibroGen, will participate in the fireside chat during the week of July 11, 2022.

How can I watch the FibroGen conference webcast?

The webcast of the FibroGen event will be available on July 11 at 9:00am ET on their Investors webpage.

What is Roxadustat and where is it approved?

Roxadustat is an approved treatment for anemia in chronic kidney disease patients in countries including China, Japan, and Europe.

What therapeutic areas does FibroGen focus on?

FibroGen focuses on developing therapeutics for unmet needs, including cancer, anemia, and autoimmune diseases.

What is Pamrevlumab used for?

Pamrevlumab is in clinical development for conditions like idiopathic pulmonary fibrosis and pancreatic cancer.